文献速递肝病消化道出血

6 mm与8 mm经颈静脉肝内门体分流术治疗静脉曲张出血的疗效:一项随机对照试验

Efficacy of 6-mm and 8-mm Transjugular Intrahepatic Portosystemic Shunt for Variceal Bleeding: A Randomized Controlled Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-07

这项由研究者发起的开放标签单中心平行随机对照试验纳入144例肝硬化静脉曲张出血患者,随机分入6 mm或8 mm覆膜支架经颈静脉肝内门体分流术组,主要终点为2年全因再出血。6 mm组再出血率较高但生存率相似,显性肝性脑病风险显著低于8 mm组。

要点

  • 6 mm组与8 mm组2年累积再出血率分别为35.2%与24.1%(P=.187),差异未达统计学显著。
  • 8 mm组2年显性肝性脑病累积发生率显著高于6 mm组(42.0% vs 20.3%;P=.009)。
  • 6 mm组与8 mm组2年实际生存率分别为84.6%与83.0%。

核心结论

  • 在因静脉曲张出血二级预防接受经颈静脉肝内门体分流术的肝硬化患者中,与8 mm支架相比,6 mm支架再出血率较高,但生存率相似,显性肝性脑病风险显著较低。

研究设计与样本

  • 研究者发起的开放标签单中心平行随机对照试验,纳入144例肝硬化静脉曲张出血患者,随机分入6 mm组(n=72)或8 mm组(n=72)。
  • 研究于2017年9月20日至2021年9月17日入组,主要终点为2年全因再出血。

主要发现

  • 6 mm组24例(33.3%)与8 mm组16例(22.2%)患者发生再出血。
  • 6 mm组与8 mm组2年累积再出血率分别为35.2%与24.1%(P=.187)。
  • 8 mm组2年显性肝性脑病累积发生率显著高于6 mm组(42.0% vs 20.3%;P=.009)。
  • 6 mm组与8 mm组2年实际生存率分别为84.6%与83.0%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Transjugular intrahepatic portosystemic shunt (TIPS) is associated with an increased incidence of hepatic encephalopathy (HE). We aimed to compare the clinical effectiveness of 6-mm and 8-mm TIPS for secondary prophylaxis of variceal bleeding in patients with cirrhosis who were at risk for HE. METHODS: This was an investigator-initiated, open-label, single-center, parallel, randomized controlled trial. Patients with cirrhosis and variceal bleeding were randomly assigned to the 6- or 8-mm covered TIPS groups. The primary endpoint was all-cause rebleeding after 2 years. RESULTS: Between September 20, 2017 and September 17, 2021, 144 patients were enrolled and randomly assigned to either the 6-mm (n = 72) or 8-mm (n = 72) TIPS group. Overall, 24 (33.3%) and 16 (22.2%) patients in the 6-mm and 8-mm groups, respectively, experienced rebleeding. In the 6-mm and 8-mm groups, the cumulative rates of rebleeding were 35.2% and 24.1%, respectively (P = .187). The 2-year cumulative incidence of overt HE was significantly higher in the 8-mm group than in the 6-mm group (42.0% vs 20.3%; P = .009). The 2-year actuarial survival rates were 84.6% in the 6-mm group and 83.0% in the 8-mm group. CONCLUSIONS: Among this cohort of patients with cirrhosis who are receiving TIPS for the secondary prevention of variceal bleeding, the use of 6-mm stents results in a higher rate of rebleeding but has similar survival and a significantly lower risk of overt HE compared with 8-mm stents. Chinese Clinical Trial Registry, No. ChiCTR-INR-17012479.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhang W, Zhang M, Xiao J, et al. Efficacy of 6-mm and 8-mm Transjugular Intrahepatic Portosystemic Shunt for Variceal Bleeding: A Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2025. PMID: 40633893. doi:10.1016/j.cgh.2025.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。